Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 30 of SEBI Listing Regulations

Audit Opinion:

Clean opinion. The unaudited standalone and consolidated financial results were reviewed by the Audit Committee, approved by the Board of Directors, and reviewed by the Statutory Auditors, Brahmayya & Co. The Limited Review Report states that nothing has come to their attention that causes them to believe the Statement contains any material misstatement.

Key Financial Highlights [₹ in Crores]:

Standalone Results:

| Particulars | Q1 FY27 (30.06.2026) | Q4 FY26 (31.03.2026) | Q1 FY26 (30.06.2025) | FY26 (31.03.2026) |

| Revenue from Operations | 202.95 | 191.36 | 182.57 | 738.33 |

| Other Income | 62.79 | 72.39 | 32.03 | 195.37 |

| Total Income | 265.74 | 263.75 | 214.60 | 933.70 |

| Net Profit | 120.38 | 120.81 | 85.89 | 396.58 |

| EPS - Basic (₹) | 15.84 | 15.89 | 11.30 | 52.17 |

| EPS - Diluted (₹) | 15.79 | 15.85 | 11.26 | 52.02 |

| Other Equity | Not Specified | Not Specified | Not Specified | 2,035.30 |

Standalone Other Income includes a dividend of ₹28.90 Cr from wholly owned subsidiary Caplin Point Far East Limited.

Consolidated Results:

| Particulars | Q1 FY27 (30.06.2026) | Q4 FY26 (31.03.2026) | Q1 FY26 (30.06.2025) | FY26 (31.03.2026) |

| Revenue from Operations | 610.36 | 600.16 | 510.22 | 2,187.19 |

| Other Income | 33.55 | 28.36 | 23.14 | 115.54 |

| Total Revenue | 643.91 | 628.52 | 533.36 | 2,302.73 |

| Profit Before Tax | 225.22 | 213.44 | 184.46 | 802.79 |

| Net Profit | 179.09 | 172.88 | 150.76 | 649.73 |

| Profit attributable to Owners | 176.91 | 170.11 | 152.80 | 641.24 |

| EPS - Basic (₹) | 23.27 | 22.38 | 20.10 | 84.36 |

| EPS - Diluted (₹) | 23.21 | 22.31 | 20.03 | 84.11 |

| Other Equity | Not Specified | Not Specified | Not Specified | 3,571.22 |

YoY Growth (Consolidated): Revenue from Operations up 19.6%, Total Revenue up 20.7%, PAT up 18.8%.

QoQ Growth (Consolidated): Revenue from Operations up 1.7%, Total Revenue up 2.4%, PAT up 3.6%.

Segment-wise Performance [₹ in Crores]:

Revenue (Q1 FY27):

  • Rest of the World: 476.07
  • USA: 134.29
  • Unallocated (Other Income): 33.55

Segment Profit (PBT) (Q1 FY27):

  • Rest of the World: 158.40
  • USA: 33.27
  • Unallocated: 33.55

Segment Assets (as of 30.06.2026):

  • Rest of the World: 2,021.21
  • USA: 672.75
  • Unallocated: 1,502.39
  • Total: 4,196.35

Segment Liabilities (as of 30.06.2026):

  • Rest of the World: 350.80
  • USA: 69.79
  • Total: 420.59

Corporate Actions:

  • Dividend: The Board recommended a Final Dividend of ₹4 (200%) per equity share of face value ₹2 each for FY26. This is subject to approval at the forthcoming AGM and shall be paid on or before October 24, 2026. A Record Date will be communicated separately.
  • This is in addition to an Interim Dividend of ₹4 (200%) per share declared on May 14, 2026, and paid on June 8, 2026. The total dividend for FY26, if the final dividend is approved, will be ₹8 per share (400%).
  • No shares were allotted under the ESOP scheme in the quarter. The total number of equity shares remains 7,60,11,696.

Other Significant Information:

Operational & Financial Metrics (Consolidated Q1 FY27):

  • Gross Margin: 59.8% (vs 61.7% in Q1 FY26)
  • EBITDA: ₹247.0 Cr, up 23.0% YoY; EBITDA Margin: 38.4% (vs 37.7% in Q1 FY26)
  • Cash Flow from Operations: ₹95 Cr (vs ₹118 Cr in Q1 FY26)
  • Free Cash Flow: ₹40 Cr (after Capex of ₹55 Cr)
  • Geographical Revenue Mix: Emerging Markets (LatAm & Africa) 78%, USA 22%
  • CSL Revenue Mix: Product Supply 85%, Milestone + Profit Share 15%
  • Inventories (30-Jun-2026): ₹505 Cr (47% at warehouses, 23% in transit, 30% in India)
  • Receivables: 128 days
  • Free Cash Reserves: ₹1,502 Cr
  • Total Liquid Assets: ₹2,875 Cr

Business Highlights & Strategic Initiatives:

Emerging Markets (LatAm & Africa):

  • Won emergency tenders across Central America (~$7 million) to be supplied over next 2 quarters.
  • Won tenders in Chile (~$12 million) to be supplied over next 18 months.
  • Received 4 additional product approvals in Mexico; pipeline of 120+ products to be filed in next 18 months.
  • Oncology facility in Kakkalur completed submission batches for 6 products; 18 more planned in next 12 months.
  • API unit in Vizag scaled up 6 APIs for backward integration; aims to file first DMFs in 2026/27.
  • Construction ongoing for new OSD and Dermatology facility in Pondy to more than double capacity.
  • Expanding Amaris Clinical capacity to 120 beds by end-FY27.

US & Regulated Markets:

  • 60 ANDAs approved, 5 under review; pipeline of 40+ products.
  • Filed 110+ products in non-US markets (65 approved); plans to file 60+ more in next 18 months.
  • Launched 38 products in US to date; plans to launch 12 more in FY27.
  • Plans to file first Pre-Filled Syringe product in FY27; pipeline of 14+ PFS products for FY28.
  • Automation of e-logbooks and batch manufacturing records underway.
  • COL-II facility construction to be completed by Mar '27 to house 5 new lines.
  • Caplin Steriles USA Inc (CSU) launched 33 products under its own label; plans 10 more in FY27.

Capex:

The company has an enhanced Capex budget of approx. ₹1000+ Cr, with 50% nearing completion and the balance to be incurred over the next 2-3 years. It will be financed solely through internal accruals.

Entities in Consolidation:

The consolidated results include the Holding Company and its subsidiaries: Caplin Steriles Limited, Argus Salud Pharma LLP, Caplin One Labs Limited, Caplin Point Far East Limited, Caplin Point (S) Pte. Ltd, and their respective step-down subsidiaries in El Salvador, Guatemala, Ecuador, Honduras, Nicaragua, Colombia, Chile, Mexico, and the USA. It also includes the share of profit from an associate, Sunsole Solar Private Limited.